-
Press Release
Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)
-
Press Release
Novartis presents promising interim Phase II data of potential first-in-class oral therapy iptacopan (LNP023) in rare renal disease C3 glomerulopathy (C3G)
-
Press Release
Novartis acquires Vedere Bio, adding novel optogenetic gene therapy technology for treating blindness
-
Story
Stopping free radicals at their source -
Story
Reimagining protein sequencing -
Story
Molecular glue kills cancer cells in mice -
Story
Minion challenges assumptions about the genome -
Story
How Zika infects the growing brain -
Story
How to address the culture gap between academia and industry in biomedicine -
Story
Hooked on science, Jay Bradner becomes top researcher at Novartis -
Story
Fixing what’s lost in translation -
Story
Eye disease tracked to a glitch in starburst cells